<DOC>
	<DOCNO>NCT01359488</DOCNO>
	<brief_summary>The purpose research study determine safety tolerability five dos VRS-317 Adult Growth Hormone Deficient patient . - Patients evaluated evidence activity VRS-317 measurement change baseline insulin-like growth factor-1 ( IGF-I ) bind protein ( IGFBP-3 ) , bone turnover ( bone alkaline phosphatase ) - Descriptive pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter ( IGF-I IGFBP-3 ) determine standard model independent method base plasma concentration-time data subject . These parameter include : Cmax , Tmax , AUCavg , AUC0-inf , t1/2 . - The purpose determine appropriate dose VRS-317 maintain normal range ( appropriate age/gender ) IGF-I level adult patient one month administration single dose</brief_summary>
	<brief_title>VRS-317 Adult Subjects With Growth Hormone Deficiency</brief_title>
	<detailed_description>The study placebo control single ascending dose ( SAD ) study adult GHD patient currently receive daily rhGH therapy . After screen patient withdrawn daily rhGH therapy minimum 7 day ( maximum 60 day ) prior randomization treatment . Patients randomise within treatment group currently enrol patient pass pre-dose screening criterion . Documented confirmation ( medical history ) GHD adulthood minimum one GH stimulation test require : - insulin tolerance test ( ITT ; peak hGH ≤ 5.0 ng/mL ) , - arginine alone ( peak hGH ≤ 0.4 ng/mL ) ; - arginine + growth-hormone-releasing hormone* ( see ) ; - glucagon stimulation test ( peak hGH ≤ 3.0 ng/mL ) OR - least 3 pituitary hormone deficiency low IGF-I age/gender appropriate normal range Each patient randomise receive either investigational product , VRS-317 ( Cohorts A-E ) , placebo ( Cohort F ) 4:1 ratio . Subjects monitor safety throughout participation study . To ensure patient safety , two patient ( 1 active , 1 placebo ) first treatment group , one Cohort A one Cohort F1 , dose blinded manner monitor 48 hr prior dose remain 8 patient . The 8 remain patient blind randomize first treatment group . Vital sign , clinical lab value , adverse event ( AEs ) concomitant medication ( CMs ) capture . AEs grade use Common Terminology Criteria Adverse Events ( CTCAE v 4.0 ) 1 , Primary Dermal Irritation Scoring Scale ; AEs cod use MedDRA2 dictionary CMs use WHO Drug dictionary . Prior escalate high dose level , safety data review principal investigator ( PI ) , co-PIs , Sponsor , medical monitor potential safety risk subject . Patients participate total 83-215 day . A 7-60 day withdrawal phase ( daily rhGH therapy ) follow receive assigned dos Day 1 Treatment Phase , PK/PD safety assessment 30 day , additional 30 day follow . Safety evaulations perform assess safety include limited : - Physical examination - Vital sign ( include sitting/supine blood pressure ) - Laboratory test : hematology , chemistry , urinalysis , pregnancy test ( woman child-bearing age ) - Adverse event concomitant medication - Glucose metabolism : Fasting post-prandial plasma glucose fast insulin pre-study pre-scheduled timepoints study ( per Assessment Table ) - Lipid profile assess pre-study pre-scheduled timepoints study ( per Assessment Table ) - Assessment adrenal insufficiency prior enrollment Day 30 ( perform patient document history adrenal insufficiency ) - Evaluation injection site reaction - Anti-VRS-317 antibody assay ( pre-dose , Day 30 ( end study ) Day 60 ) last follow visit - Safety monitoring continue 60 day post-dose</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>1 . Age 25 65 year 2 . Negative serum pregnancy test female childbearing potential 3 . Documented confirmation ( medical history ) GHD adulthood one GH stimulation test 4 . If take hormone replacement therapy rhGH , patient must stable course treatment 2 month prior enrollment 5 . Pituitary disorder associate GHD clinically stable least 6 month 6 . Currently receive daily recombinant human growth hormone ( rhGH ) injection treatment GHD minimum 28 day 7 . Willing able give inform consent 8 . Within one year enrollment , normal result screen include : mammogram ( woman ) , pap smear ( woman 25 ) , Men 50 year old : digital rectal exam 1 . Subjects receive systemic treatment bacterial , viral fungal infection within 30 day first study drug dosing ( prophylactic acyclovir HSV permit ) 2 . Subjects document history diabetes mellitus inadequate glucose control define fast plasma glucose level great 126 mg/dL ( 7 mM ) HbA1c ≥ 6.5 % screen 3 . Subjects untreated adrenal insufficiency . 4 . Free thyroxine normal reference range TSH normal reference range 5 . Current use oral inhaled steroid except physiological maintenance dose oral glucocorticoid patient multiple pituitary hormone deficiencies 6 . Women use oral estrogen , include birth control pill , study ( transdermal estrogen patch allow ) 7 . Current significant cardiovascular , cerebrovascular , pulmonary , neurological ( related GHD ) , renal hepatobillary disease 8 . Presence retinopathy papillaedema 9 . Documented history persistent ( unresolved without medical intervention ) recur migraine , edema , arthralgia ( related osteoarthritis ) , nausea 10 . History drug alcohol abuse . 11 . Must document prior history HIV , HBV HCV infection ( test require ) 12 . Prior history cancer exclude adequately treat nonmelanoma skin cancer adequately treat situ carcinoma cervix 13 . Women pregnant breastfeed 14 . Unwilling use two effective birth control method Day 60 Treatment Phase 15 . Preexisting antibody human growth hormone time screen ( screen sample must prespecified cutoff positive antihGH antibody titer ) 16 . Treatment investigational drug within past 30 day prior screen 17 . Unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>rhGH</keyword>
	<keyword>hGH</keyword>
	<keyword>Versartis</keyword>
	<keyword>AGHD</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormone substitute</keyword>
	<keyword>Endocrin System disease</keyword>
	<keyword>Bone disease</keyword>
	<keyword>Bone disease , developmental</keyword>
	<keyword>Bone disease</keyword>
	<keyword>Musculoskeletal disease</keyword>
	<keyword>Bone disease , endocrine</keyword>
	<keyword>Metabolism disease</keyword>
	<keyword>Hypopituitarism</keyword>
	<keyword>Pituitary disease</keyword>
	<keyword>Hypothalmic disease</keyword>
	<keyword>Brain disease</keyword>
	<keyword>Growth Hormone Releasing Hormone</keyword>
	<keyword>Hormone replacement therapy</keyword>
	<keyword>IGF-I</keyword>
	<keyword>IGFBP-3</keyword>
</DOC>